Literature DB >> 6419809

"Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

D McAreavey, L E Ramsey, L Latham, A D McLaren, A R Lorimer, J L Reid, J I Robertson, M P Robertson, R J Weir.   

Abstract

Hydralazine, labetalol, methyldopa, minoxidil, prazosin, and placebo were compared when added by random allocation to atenolol 100 mg and bendrofluazide 5 mg daily in a series of 238 hypertensive patients inadequately controlled by the beta blocker-diuretic combination. Atenolol was withdrawn in those allocated to labetalol, and minoxidil was given only to men. The order of acceptability was: placebo, hydralazine, prazosin, methyldopa, minoxidil, labetalol. Minoxidil was more effective than the other active drugs, which had similar potency to one another. All the active agents were more effective than placebo. Hydralazine was the most generally suitable third drug, with prazosin a close second. Minoxidil was especially effective in patients with less severe hypertension but the same regimen caused fluid retention in those with more severe disease. Labetalol should probably be introduced at a low dose (150 mg daily) even when replacing full doses of a previously administered beta blocker.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6419809      PMCID: PMC1443950          DOI: 10.1136/bmj.288.6411.106

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


  21 in total

1.  Minoxidil for severe hypertension after failure of other hypotensive drugs.

Authors:  B L Devine; R Fife; P M Trust
Journal:  Br Med J       Date:  1977-09-10

2.  Studies with prazosin--a new effective hypotensive agent. I. Open clinical study of prazosin in combination with other antihypertensive agents.

Authors:  A S Hua; I M Macdonald; J B Myers; P Kincaid-Smith
Journal:  Med J Aust       Date:  1976-04-17       Impact factor: 7.738

3.  A symptom questionnaire for hypertensive patients.

Authors:  C J Bulpitt; C T Dollery; S Carne
Journal:  J Chronic Dis       Date:  1974-08

4.  A random-zero sphygmomanometer.

Authors:  B M Wright; C F Dore
Journal:  Lancet       Date:  1970-02-14       Impact factor: 79.321

5.  Labetalol in long-term treatment of hypertension.

Authors:  B N Prichard; A J Boakes
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Methyldopa and propranolol or practolol in moderate hypertension.

Authors:  J C Petrie; D B Galloway; T A Jeffers; H R Millar; M C Smith; R A Wood; J A Lewis; W T Simpson
Journal:  Br Med J       Date:  1976-07-17

7.  Atenolol, methyldopa, and chlorthalidone in moderate hypertension.

Authors:  J Webster; T A Jeffers; D B Galloway; J C Petrie; N P Barker
Journal:  Br Med J       Date:  1977-01-08

8.  Contribution of atenolol, bendrofluazide, and hydrallazine to management of severe hypertension.

Authors:  R G Wilcox; J R Mitchell
Journal:  Br Med J       Date:  1977-08-27

9.  A comparison of minoxidil and hydralazine in non-azotemic hypertensives.

Authors:  B F Johnson; H R Black; R Beckner; B Weiner; F Angeletti
Journal:  J Hypertens       Date:  1983-06       Impact factor: 4.844

10.  Prazosin: preliminary report and comparative studies with other antihypertensive agents.

Authors:  G S Stokes; M A Weber
Journal:  Br Med J       Date:  1974-05-11
View more
  22 in total

Review 1.  Resistant hypertension and the Birmingham Hypertension Square.

Authors:  D C Felmeden; G Y Lip
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

2.  Proceedings of the British Pharmacological Society, British Pharmacology Section. 18-20 April 1990, Sheffield. Abstracts.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  1990-08       Impact factor: 4.335

Review 3.  Compliance in clinical trials.

Authors:  T Pullar; S Kumar; M Feely
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

Review 4.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

5.  Initial therapy for patients with uncomplicated hypertension.

Authors:  R B Haynes
Journal:  Can Fam Physician       Date:  1985-02       Impact factor: 3.275

6.  Ketanserin, an effective third-line agent in primary hypertension.

Authors:  J J Murphy; P H Whincup; S E Gould; R G Wilcox
Journal:  Drugs       Date:  1988       Impact factor: 9.546

7.  A need for new converting enzyme inhibitors?

Authors:  S G Ball; J I Robertson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-01-19

8.  A comparison of labetalol and prazosin combined with atenolol in non-responders to atenolol plus hydrochlorothiazide in uncomplicated hypertension.

Authors:  E van der Veur; B S ten Berge; A J Donker; J F May; F H Schuurman; H Wesseling
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

9.  A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.

Authors:  J Webster; J C Petrie; O J Robb; M Jamieson; J Verschueren
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

Review 10.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.